Meeting
2020 ASCO Virtual Scientific Program
Brentuximab vedotin and bendamustine as first-line treatment of Hodgkin lymphoma in the elderly (HALO Trial).
Authors
Jean Marc Schiano de Colella
Institut Paoli-Calmettes, Marseille, France
Jean Marc Schiano de Colella , Simonetta Viviani , Davide Rapezzi , CATERINA PATTI , Lauriane Clement Filliatre , Andrea Rossi , Fontanet Bijou , Maria Cantonetti , Cécile Borel , Brice Thamphya , Renaud Schiappa , Emmanuel Chamorey , Colin Debaigt , Lauris Gastaud , Antoine Thyss , Andrea Gallamini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Hodgkin Lymphoma
Clinical Trial Registration Number
NCT02467946
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8029)
DOI
10.1200/JCO.2020.38.15_suppl.8029
Abstract #
8029
Poster Bd #
362
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple (RRMM): A subgroup analysis from MagnetisMM-3.
First Author: Noopur S. Raje
Poster
2023 ASCO Annual Meeting
Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).
First Author: Cyrille Touzeau
Poster
2023 ASCO Annual Meeting
KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.
First Author: David Lavie
Poster
2020 ASCO Virtual Scientific Program
Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients.
First Author: Christopher A. Yasenchak